Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (61-70 of 301) with videos related to

Pageof 31
Sort By:
Health Affairs (Project Hope)|January 14, 2005
When is evidence sufficient?Karl Claxton, Joshua T Cohen, Peter J Neumann
American Journal of Preventive Medicine|December 1, 2012
A role for research: an observation on preventive services for womenNatalia Olchanski, Joshua T Cohen, Peter J Neumann
Journal of Managed Care & Specialty Pharmacy|June 29, 2018
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for HemophiliaTeja Thorat, Peter J Neumann, James D Chambers
Value in Health Regional Issues|April 27, 2018
The State of Cost-Utility Analyses in Asia: A Systematic ReviewTeja Thorat, Pei-Jung Lin, Peter J Neumann
The New England Journal of Medicine|November 12, 2021
Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?Peter J Neumann, Joshua T Cohen, Daniel A Ollendorf
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 4, 2019
Embracing the science of value in healthMurray Krahn, Stirling Bryan, Karen Lee, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 17, 2010
Does Medicare have an implicit cost-effectiveness threshold?James D Chambers, Peter J Neumann, Martin J Buxton
Pharmacoeconomics|October 7, 2009
30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvementPeter J Neumann, Chi-Hui Fang, Joshua T Cohen
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value FrameworksJoshua T Cohen, Jordan E Anderson, Peter J Neumann
Health Affairs (Project Hope)|September 13, 2006
Biotechnology and Medicare's new technology policy: lessons from three case studiesPatricia Seliger Keenan, Peter J Neumann, Kathryn A Phillips
Pageof 31

Showing results (61-70 of 301) with videos related to

Sort By:
Pageof 31
Health Affairs (Project Hope)|January 14, 2005
When is evidence sufficient?Karl Claxton, Joshua T Cohen, Peter J Neumann
American Journal of Preventive Medicine|December 1, 2012
A role for research: an observation on preventive services for womenNatalia Olchanski, Joshua T Cohen, Peter J Neumann
Journal of Managed Care & Specialty Pharmacy|June 29, 2018
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for HemophiliaTeja Thorat, Peter J Neumann, James D Chambers
Value in Health Regional Issues|April 27, 2018
The State of Cost-Utility Analyses in Asia: A Systematic ReviewTeja Thorat, Pei-Jung Lin, Peter J Neumann
The New England Journal of Medicine|November 12, 2021
Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?Peter J Neumann, Joshua T Cohen, Daniel A Ollendorf
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 4, 2019
Embracing the science of value in healthMurray Krahn, Stirling Bryan, Karen Lee, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 17, 2010
Does Medicare have an implicit cost-effectiveness threshold?James D Chambers, Peter J Neumann, Martin J Buxton
Pharmacoeconomics|October 7, 2009
30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvementPeter J Neumann, Chi-Hui Fang, Joshua T Cohen
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value FrameworksJoshua T Cohen, Jordan E Anderson, Peter J Neumann
Health Affairs (Project Hope)|September 13, 2006
Biotechnology and Medicare's new technology policy: lessons from three case studiesPatricia Seliger Keenan, Peter J Neumann, Kathryn A Phillips
Pageof 31